OBJECTIVE: To evaluate the influence of the type and treatment of CNS lesion causing central precocious puberty (CPP) on the presentation, hypothalamic-pituitary function and final height. PATIENTS: One hundred patients with CPP caused by central nervous system (CNS) lesion. RESULTS: The CPP was the presenting symptom of the lesion in 25 (10 boys) and occurred in 75 patients (23 boys) previously treated for lesions. These were optic glioma or astrocytoma (n = 45), hydrocephalus (n = 22), hypothalamic hamartoma (n = 15), suprasellar arachnoid cyst (n = 10) and others (n = 8). The percentages of patients with increased height, bone age advance, testicular volume, LH/FSH peaks ratio after gonadotrophin-releasing hormone (GnRH) test and plasma testosterone concentration in boys and oestradiol in girls varied from one aetiology to another. The boys with hamartoma were significantly taller and had greater bone age advance, LH peak and testosterone than boys with optic glioma. The girls with hamartoma and suprasellar arachnoid cyst were significantly younger and had greater LH peak than girls in the other groups. All patients treated for optic glioma had hypothalamic-pituitary deficiencies, including GH (100%), thyrotrophin (71.4%), corticotrophin (12.5%) and pubertal (34.3%) deficiencies. Sixty percent of those with suprasellar cysts lacked GH. Final height was below -2 SD in 15/59 (25%) patients, including 5/11 not treated with GnRH analogue, 3/5 not treated with GH despite GH deficiency, and 2 with hydrocephalus as a result of meningomyelocele. CONCLUSIONS: The type of CNS lesion influences the presentation of CPP. This is probably caused by differences in the mechanisms inducing puberty and to the hypothalamic-pituitary deficiencies associated with the CPP as a result of a lesion and/or its treatment.
OBJECTIVE: To evaluate the influence of the type and treatment of CNS lesion causing central precocious puberty (CPP) on the presentation, hypothalamic-pituitary function and final height. PATIENTS: One hundred patients with CPP caused by central nervous system (CNS) lesion. RESULTS: The CPP was the presenting symptom of the lesion in 25 (10 boys) and occurred in 75 patients (23 boys) previously treated for lesions. These were optic glioma or astrocytoma (n = 45), hydrocephalus (n = 22), hypothalamic hamartoma (n = 15), suprasellar arachnoid cyst (n = 10) and others (n = 8). The percentages of patients with increased height, bone age advance, testicular volume, LH/FSH peaks ratio after gonadotrophin-releasing hormone (GnRH) test and plasma testosterone concentration in boys and oestradiol in girls varied from one aetiology to another. The boys with hamartoma were significantly taller and had greater bone age advance, LH peak and testosterone than boys with optic glioma. The girls with hamartoma and suprasellar arachnoid cyst were significantly younger and had greater LH peak than girls in the other groups. All patients treated for optic glioma had hypothalamic-pituitary deficiencies, including GH (100%), thyrotrophin (71.4%), corticotrophin (12.5%) and pubertal (34.3%) deficiencies. Sixty percent of those with suprasellar cysts lacked GH. Final height was below -2 SD in 15/59 (25%) patients, including 5/11 not treated with GnRH analogue, 3/5 not treated with GH despite GH deficiency, and 2 with hydrocephalus as a result of meningomyelocele. CONCLUSIONS: The type of CNS lesion influences the presentation of CPP. This is probably caused by differences in the mechanisms inducing puberty and to the hypothalamic-pituitary deficiencies associated with the CPP as a result of a lesion and/or its treatment.
Authors: David Gass; Mariko Dewire; Lionel Chow; Susan R Rose; Sarah Lawson; Charles Stevenson; Ahna L H Pai; Blaise Jones; Mary Sutton; Adam Lane; David Pruitt; Maryam Fouladi; Trent R Hummel Journal: J Neurooncol Date: 2015-01-13 Impact factor: 4.130
Authors: Wassim Chemaitilly; Thomas E Merchant; Zhenghong Li; Nicole Barnes; Gregory T Armstrong; Kirsten K Ness; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Melissa M Hudson; Charles A Sklar; Amar Gajjar Journal: Clin Endocrinol (Oxf) Date: 2015-11-16 Impact factor: 3.478
Authors: Raja Brauner; Anu Bashamboo; Sébastien Rouget; Marie Goulet; Pascal Philibert; Hélène Sarda-Thibault; Christine Trivin; Micheline Misrahi; Charles Sultan; Ken McElreavey Journal: PLoS One Date: 2010-06-25 Impact factor: 3.240
Authors: Signe Sloth Mogensen; Lise Aksglaede; Annette Mouritsen; Kaspar Sørensen; Katharina M Main; Peter Gideon; Anders Juul Journal: PLoS One Date: 2012-01-12 Impact factor: 3.240
Authors: Keun Hee Choi; Seung Joon Chung; Min Jae Kang; Ju Young Yoon; Ji Eun Lee; Young Ah Lee; Choong Ho Shin; Sei Won Yang Journal: Ann Pediatr Endocrinol Metab Date: 2013-12-31